Crossmark

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations

Crossref DOI link: https://doi.org/10.1007/s12032-018-1098-3

Published Online: 2018-02-08

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tanaka, Hisashi https://orcid.org/0000-0003-2009-0210
Taima, Kageaki

Tanaka, Yoshihito

Itoga, Masamichi

Ishioka, Yoshiko

Nakagawa, Hideyuki

Baba, Keisuke

Hasegawa, Yukihiro

Takanashi, Shingo

Tasaka, Sadatomo
License Information

Text and Data Mining valid from 2018-02-08
More Information

Article History

Received: 16 January 2018

Accepted: 5 February 2018

First Online: 8 February 2018

Compliance with ethical standards

:

: All the authors declare that they have no conflict interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the institutional review boards of all participating institutions. This study was registered with the University Hospital Medical Information Network (UMIN), Number UMIN000011696.

: Informed consent was obtained from all individual participants included in the study.